https://scholars.lib.ntu.edu.tw/handle/123456789/568528
標題: | HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection | 作者: | SHIH-JER HSU Hsu C.-S. CHEN-HUA LIU CHUN-JEN LIU CHI-LING CHEN PEI-JER CHEN DING-SHINN CHEN JIA-HORNG KAO |
公開日期: | 2011 | 出版社: | International Medical Press Ltd | 卷: | 16 | 期: | 2 | 起(迄)頁: | 227-235 | 來源出版物: | Antiviral Therapy | 摘要: | Background: Amino acid (aa) substitutions in genotype 1 HCV core region (HCV-CR) serve as a negative predictor of treatment responses in Japanese chronic hepatitis C (CHC) patients. Whether this phenomenon could be extrapolated to non-Japanese patients remains unclear. We evaluated the effect of aa substitutions in HCV-CR on clinicopathological features and treatment responses in Taiwanese patients. Methods: Clinical and serial virological data were collected from 147 consecutive Taiwanese HCV genotype 1 patients who received pegylated interferon plus ribavirin therapy. Quantification of HCV RNA and sequences of HCV-CR were determined by molecular methods. Results: Of 147 patients, 90 (61.2%) attained rapid virological response (RVR) and 97 (66.0%) attained sustained virological response (SVR). Patients without aa substitutions in HCV-CR (coreWW) had a higher SVR than those with both aa70 and aa91 substitutions (coreMM; 70.5% versus 45.0%; P=0.039). Moreover, coreMM was associated with a higher γ-glutamyl transpeptidase level (P=0.026) as well as more severe liver fibrosis (P=0.027) than coreWW, and patients with aa70 substitution (coreMW) were associated with more severe liver steatosis and fibrosis than those without (P=0.020 and P=0.002, respectively). In multivariate analyses, lower pretreatment body mass index, milder liver fibrosis, 48 weeks of treatment and RVR, but not aa substitutions in HCV-CR, predicted a higher SVR rate. Conclusions: Although aa substitution in genotype 1 HCV-CR is associated with more severe liver fibrosis and might be a negative predictor of SVR in Taiwanese CHC patients with interferon-based therapy, RVR and other clinical factors outweigh its role in predicting SVR. ?2011 International Medical Press. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984562879&doi=10.3851%2fIMP1741&partnerID=40&md5=9acbecf671ac654b29e1bf16e6461f54 https://scholars.lib.ntu.edu.tw/handle/123456789/568528 |
ISSN: | 1359-6535 | DOI: | 10.3851/IMP1741 | SDG/關鍵字: | amino acid; core protein; gamma glutamyltransferase; peginterferon alpha2a; ribavirin; virus RNA; adult; amino acid substitution; article; body mass; clinical feature; controlled study; core gene; disease severity; DNA polymorphism; drug efficacy; fatty liver; female; gamma glutamyl transferase blood level; genotype; hepatitis C; Hepatitis C virus; human; liver biopsy; liver fibrosis; major clinical study; male; nucleotide sequence; prediction; priority journal; RNA analysis; sequence analysis; Taiwan; treatment response; virus gene |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。